AstraZeneca stock? I don’t think it’ll be a winner for 2020 and beyond

Markets are now a little bit sceptical about AstraZeneca. Why? Anna Sokolidou shares her thoughts on the pharma giant.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many investors got excited recently on the back of a Bloomberg report of a potential merger between AstraZeneca  (LSE:AZN) and Gilead Sciences, a large American biopharmaceutical company. Such a deal would have involved close co-operation in researching and developing a coronavirus vaccine.

But this excitement didn’t last long as AstraZeneca ruled out talks about such a deal. It was probably a smart decision to do so since the pharmaceutical giant is best known for its excellent cancer drug pipeline. So focusing on its core competency should lead to better profits. Even though investing heavily in a Covid-19 vaccine might have given it a newsworthy boost, developing and testing one is a very long and costly process with no certainty of success. 

I’ve read plenty of news in the press about small healthcare companies trying to develop Covid-19 vaccines. However, they all turned out to be rumours in the end. The point I’m making is that no one can guarantee that a particular company or a group of companies will develop an effective one. Even if it does happen, testing, marketing and launching one would take time and resources. So it would take a while for any vaccine to start generating positive cash flows.  

We all know that even a rumour of a Covid-19 vaccine developed by a particular company makes that company’s shares skyrocket, thus making it a less attractive buy for a value investor. So in the end, it might be good news that a merger between Gilead and AstraZeneca was a non-starter.

But is the latter a good buy or not as it stands? Let’s look at its fundamentals.

The numbers

Some may be flocking to AZN shares but hedge funds aren’t particularly enthusiastic about the firm. The company isn’t in the top 30 positions in most large funds’ portfolios. And the hedgies have very good reasons to avoid being too positive on these shares, I feel.

I totally agree with my colleague Kirsteen Mackay that the company looks overvalued. Apart from a very high price-to-earnings (P/E) ratio of more than 100, its revenue and earnings growth is unimpressive to me. A much lower P/E ratio of 20 would be about average, but even this wouldn’t make a company’s stock a bargain. And a ratio over and above that really has to be justified. A company with such a big multiplier as AZN has to have truly impressive earnings and revenue growth.

AstraZeneca’s earnings per share (EPS) hardly increased between 2018 and 2019. In 2018, EPS had been $3.46, but in 2019 they rose marginally to $3.50 per share. Revenue growth was better and totalled 15% between 2018 and 2019, but without profits growth to match, that’s not exactly exciting. 

AstraZeneca does, however, pay dividends. Yet the dividend yield is below 3% and lower than FTSE 100’s average of more than 4%. 

This is what I’d do now 

Even though AstraZeneca is a market leader, I’d probably avoid investing in a company with numbers like it has. The firm’s shares are really expensive and I feel this price can’t be justified. I’d look elsewhere.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Anna Sokolidou has no position in any of the shares mentioned in this article.The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 in savings? Here’s how it could be used to target a £913 second income each month

Christopher Ruane walks through some practicalities of how an idle £20k could be the foundation for a sizeable long-term second…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

5 steps to building monthly passive income with a spare £10k

Christopher explains how an investor could aim to use some spare cash to start building regular passive income streams through…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

Tesla’s struggling. Could NIO stock benefit?

NIO stock has moved up very slightly this year, while Tesla has crashed. Our writer considers whether it might be…

Read more »

Two employees sat at desk welcoming customer to a Tesla car showroom
Investing Articles

Could Tesla stock be a brilliant bargain in plain sight?

Christopher Ruane sees some things to like about Tesla, but as its vehicle revenues have gone into sharp decline, is…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

3 cheap FTSE 250 stocks with big dividends to consider buying right now

The FTSE 250's loaded with so many big dividend yields it's hard to know where to start. These three have…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up 585%, could Rolls-Royce shares still go higher?

Christopher Ruane likes the Rolls-Royce business but is not so convinced by the value its current share price offers him.…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

I reckon a bull market’s coming! Here’s what I’m buying for my Stocks and Shares ISA

Hoping to capitalise on what he believes is an undervalued UK stock market, our writer’s added more of this FTSE…

Read more »

piggy bank, searching with binoculars
Investing Articles

The UK stock market looks undervalued to me. Here’s 1 growth stock to consider for a SIPP

Our writer explains why he thinks the UK stock market’s currently in bargain territory, and identifies one share potentially worthy…

Read more »